Loading company…
Nanjing Sainuo Biotechnology develops biological drugs for diabetes, including GLP-1 and insulin products.
Established in 2018 and based in Nanjing, China, Nanjing Sainuo Biotechnology Co., Ltd. develops biological drugs for diabetes, mainly GLP-1 and insulin biopharmaceuticals. Its revenue comes from providing these biologic drugs. In March 2020 the firm closed a pre-Series A funding round.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in